NAUT - NASDAQ

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Earnings Call Transcripts

NAUT · NASDAQ

Related Guides

Blog Categories

Continue your NAUT research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.